A novel CSP C-Terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum

Nathan Beutler*, Tossapol Pholcharee, David Oyen, Yevel Flores-Garcia, Randall S. MacGill, Elijah Garcia, Jaeson Calla, Mara Parren, Linlin Yang, Wayne Volkmuth, Emily Locke, Jason A. Regules, Sheetij Dutta, Daniel Emerling, Angela M. Early, Daniel E. Neafsey, Elizabeth Winzeler, C. Richter King, Fidel Zavala, Dennis R. BurtonIan A. Wilson, Thomas F. Rogers

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Potent and durable vaccine responses will be required for control of malaria caused by Plasmodium falciparum (Pf). RTS,S/AS01 is the first, and to date, the only vaccine that has demonstrated significant reduction of clinical and severe malaria in endemic cohorts in Phase 3 trials. Although the vaccine is protective, efficacy declines over time with kinetics paralleling the decline in antibody responses to the Pf circumsporozoite surface protein (PfCSP). Although most attention has focused on antibodies to repeat motifs on PfCSP, antibodies to other regions may play a role in protection. Here, we expressed and characterized seven monoclonal antibodies to the C-Terminal domain of CSP (ctCSP) from volunteers immunized with RTS,S/AS01. Competition and crystal structure studies indicated that the antibodies target two different sites on opposite faces of ctCSP. One site contains a polymorphic region (denoted α-ctCSP) and has been previously characterized, whereas the second is a previously undescribed site on the conserved β-sheet face of the ctCSP (denoted β-ctCSP). Antibodies to the β-ctCSP site exhibited broad reactivity with a diverse panel of ctCSP peptides whose sequences were derived from field isolates of P. falciparum whereas antibodies to the α-ctCSP site showed very limited cross reactivity. Importantly, an antibody to the β-site demonstrated inhibition activity against malaria infection in a murine model. This study identifies a previously unidentified conserved epitope on CSP that could be targeted by prophylactic antibodies and exploited in structure-based vaccine design.

Original languageEnglish
Article numbere1010409
JournalPLoS Pathogens
Issue number3
StatePublished - Mar 2022
Externally publishedYes


Dive into the research topics of 'A novel CSP C-Terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum'. Together they form a unique fingerprint.

Cite this